Welcome to our dedicated page for Ultragenyx Pharm SEC filings (Ticker: RARE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing a biotech filing packed with gene-therapy data can take hours. Ultragenyx Pharmaceutical’s SEC reports dive deep into pivotal-trial outcomes, Orphan Drug milestones, and royalty economics that move RARE’s share price. If you’ve ever scrolled through a 300-page 10-K looking for one clinical-stage update, you know the struggle.
Stock Titan solves that problem. Our AI models read every Ultragenyx quarterly earnings report 10-Q filing, flagging changes in cash runway and R&D spend. The same engine converts a dense 10-K into plain-language highlights, so understanding Ultragenyx SEC documents with AI feels effortless. Real-time alerts surface Ultragenyx Form 4 insider transactions—letting you see when executives adjust positions before key data readouts—while 8-K material events explained by the platform keep you ahead of trial announcements.
Need specifics? Explore:
- Ultragenyx insider trading Form 4 transactions and executive stock transactions Form 4 in real time.
- Ultragenyx annual report 10-K simplified with pipeline milestones, manufacturing risk factors, and revenue segmentation.
- Ultragenyx earnings report filing analysis that tracks quarter-over-quarter burn rate.
- Ultragenyx proxy statement executive compensation benchmarks against peer biotechs.
- Ultragenyx 8-K material events explained—whether it’s FDA feedback or partnership updates.
Every document arrives seconds after EDGAR posts, and AI-powered summaries convert jargon into actionable context. Stop combing through PDFs; start focusing on clinical catalysts, insider sentiment, and the bottom line—all from one streamlined dashboard.
Ultragenyx (Nasdaq: RARE) filed an 8-K disclosing receipt of FDA Breakthrough Therapy Designation for GTX-102 (apazunersen) to treat Angelman syndrome.
The decision is supported by positive Phase 1/2 data in 74 children (ages 4-17) showing rapid, sustained and continuing developmental gains over up to three years.
Breakthrough status grants intensive FDA guidance, rolling review and potential priority review, which could materially shorten development timelines and lower regulatory risk.
The filing includes customary forward-looking statements covering clinical, regulatory and manufacturing uncertainties but announces no new financial terms.
Form 4 filing reveals insider trading activity at Ultragenyx Pharmaceutical (RARE) by Director Corazon (Corsee) D. Sanders. On June 20, 2025, Sanders executed a significant sale of company shares:
- Disposed of 2,405 shares at a price of $37.39 per share
- Transaction value: approximately $89,873
- Retained ownership: 15,344 shares held directly
This insider sale represents a notable reduction in Sanders' direct holdings in Ultragenyx. The transaction was executed as a standard sale (transaction code 'S') and was reported within the required SEC filing deadline. No derivative securities transactions were reported in this filing.
Ultragenyx Pharmaceutical Inc. (RARE) has filed a Form 144 with the U.S. Securities and Exchange Commission to notify the market of a proposed secondary sale of its equity.
- Securities: 2,405 shares of common stock
- Acquisition date & type: Restricted stock received on 05/15/2025 from the issuer
- Broker: Morgan Stanley Smith Barney LLC, 1 New York Plaza, 8th Floor, New York, NY 10004
- Planned sale date: Approximately 06/20/2025 on the NASDAQ exchange
- Estimated market value: US $89,922.95
- Total shares outstanding: 94,542,035 ⇒ proposed sale equals roughly 0.0025% of shares outstanding
- Prior 3-month sales: None reported
The filing is marked as LIVE and contains the standard representation that the seller is unaware of any undisclosed material adverse information. No additional financial data or strategic developments are included in this notice. Given the very small size of the transaction relative to Ultragenyx’s share base, the filing appears routine with limited market impact.
FAQ
What is the current stock price of Ultragenyx Pharm (RARE)?
What is the market cap of Ultragenyx Pharm (RARE)?
What is Ultragenyx Pharmaceutical Inc.?
What types of diseases does Ultragenyx target?
How does Ultragenyx generate revenue?
What differentiates Ultragenyx in the rare disease space?
What is the significance of orphan and rare pediatric disease designations?
How does Ultragenyx approach clinical trial design?
What role do patient advocacy groups play for Ultragenyx?
How does Ultragenyx maintain its focus on quality and regulatory compliance?
